Opportunity Information: Apply for RFA RM 09 008
Apply for RFA RM 09 008
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Development of New Technologies Needed for Studying the Human Microbiome (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.310 Trans NIH Research Support.
- This funding opportunity was created on Jul 16, 2009 and posted on Jul 16, 2009.
- Applicants must submit their applications by Sep 14, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,000,000.00 to eligible and selected applicants.
- Eligible applicants include: For profit organizations other than small businesses Private institutions of higher education Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) .
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity RFA-RM-09-008, titled "Development of New Technologies Needed for Studying the Human Microbiome (R01)," supports research aimed at solving a very practical bottleneck in human microbiome science: getting high-quality samples of individual microbes from the human body that can be fully genome sequenced. In many microbiome studies, researchers can detect which organisms are present by sequencing mixed community DNA, but it is much harder to isolate single strains cleanly and consistently, grow or capture them in a usable form, and then generate complete reference genomes. This FOA is designed to fund the development of new or improved technologies that make it easier to obtain individual microbial isolates or strains from the human microbiota in a way that is suitable for complete genomic sequence analysis. The broader scientific payoff is an expanded catalog of reference microbial genomes, which is essential for interpreting complex microbial communities living on and in the human body and for improving downstream analyses such as taxonomic classification, functional inference, strain-level tracking, and comparative genomics.
The grant uses the NIH Research Project Grant (R01) mechanism, meaning it is intended for more substantial, well-developed projects rather than early-stage exploratory work. Awards under this FOA can be supported for up to three years. The announcement notes that it runs in parallel with a companion FOA of the same scientific scope, RFA-RM-09-009, which uses the R21 mechanism. In practice, that parallel structure signals that NIH is trying to stimulate both larger, more comprehensive technology-development efforts (R01) and smaller, potentially higher-risk or proof-of-concept efforts (R21), all aligned to the same microbiome isolate-and-sequence challenge.
For funding, NIH estimated a combined total of $2,000,000 in FY2010 for both this R01 FOA and the parallel R21 FOA together. Within that combined pool, NIH anticipated making roughly 2 to 4 R01 awards and 2 to 6 R21 awards, depending on the quality and volume of applications. As with many federal opportunities, awards were explicitly contingent on the availability of appropriated funds and on the submission of a sufficient number of meritorious applications.
Eligibility is broad and includes many organization types: public and private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3) organizations), state governments, small businesses, and for-profit organizations other than small businesses. The eligibility language also highlights a range of additional eligible applicants such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, regional organizations, eligible federal agencies, and even non-U.S. entities (foreign organizations). The FOA does not require cost sharing or matching funds, which can reduce administrative barriers for applicants and helps ensure that scientific merit and feasibility drive proposals rather than an applicant's ability to contribute extra funds.
Administratively, the opportunity is categorized as a discretionary grant within the health funding activity area and is tied to CFDA 93.310 (Trans-NIH Research Support), reflecting that it is part of a broader NIH-wide effort rather than being confined to a single institute's disease area. The FOA was posted on July 16, 2009, with an application due date of September 14, 2009, and an archive date of October 15, 2009. The primary federal agency is the National Institutes of Health, and applicants were directed to the NIH grants page for the full announcement, with NIH Office of Extramural Research (OER) webmaster contacts provided for access or linking issues.
In short, this R01 opportunity was built to accelerate microbiome research by funding technology advances that make it easier to isolate individual human-associated microbes and generate complete genome sequences for them. By increasing the number and diversity of high-quality reference genomes, NIH aimed to strengthen the foundation for analyzing and understanding the human microbiome as a complex ecosystem, enabling more accurate, detailed, and clinically relevant microbiome science.
FAQs: NIH RFA-RM-09-008 - Development of New Technologies Needed for Studying the Human Microbiome (R01)
What is RFA-RM-09-008?
RFA-RM-09-008 is a National Institutes of Health (NIH) funding opportunity announcement (FOA) titled "Development of New Technologies Needed for Studying the Human Microbiome (R01)." It supports research projects that develop new or improved technologies to help researchers obtain individual microbial isolates or strains from the human microbiota in forms that can be fully genome sequenced.
What problem is this FOA trying to solve?
The FOA targets a practical bottleneck in human microbiome research: consistently getting high-quality samples of individual microbes from the human body that can be isolated (or otherwise captured as individual strains) and used for complete genomic sequence analysis. While many studies can sequence mixed community DNA to detect which organisms are present, isolating single strains cleanly and reliably and generating complete reference genomes is much harder.
What kinds of projects does this FOA support?
This FOA supports technology development projects that make it easier to obtain individual microbial isolates or strains from the human microbiota in a way that is suitable for complete genome sequencing. The emphasis is on enabling the production of high-quality reference microbial genomes by improving the upstream steps (isolation/capture and preparation of individual organisms or strains) needed for complete sequencing.
What is the expected scientific payoff of the funded technologies?
The broader goal is to expand the catalog of reference microbial genomes associated with the human body. A larger and more diverse set of reference genomes helps strengthen downstream microbiome analyses, including taxonomic classification, functional inference, strain-level tracking, and comparative genomics.
What funding mechanism does this FOA use?
The FOA uses the NIH Research Project Grant (R01) mechanism. This generally indicates support for more substantial, well-developed projects rather than smaller early-stage exploratory efforts.
How long can projects be supported under this FOA?
Awards under this FOA can be supported for up to three years.
Is there a related or companion funding opportunity?
Yes. This FOA runs in parallel with a companion FOA, RFA-RM-09-009, which has the same scientific scope but uses the R21 mechanism. The parallel structure is meant to encourage both larger, comprehensive technology-development projects (R01) and smaller proof-of-concept or potentially higher-risk projects (R21).
How much funding did NIH estimate for this effort?
NIH estimated a combined total of $2,000,000 in FY2010 for both this R01 FOA (RFA-RM-09-008) and the parallel R21 FOA (RFA-RM-09-009) together.
How many awards were expected?
Within the combined funding pool for the R01 and R21 FOAs, NIH anticipated roughly 2 to 4 R01 awards and 2 to 6 R21 awards, depending on the quality and volume of applications.
Are awards guaranteed if an application is strong?
No. The FOA notes that awards are contingent on the availability of appropriated funds and on the submission of a sufficient number of meritorious applications.
Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education, nonprofit organizations (both 501(c)(3) and non-501(c)(3)), state governments, small businesses, and for-profit organizations other than small businesses. The eligibility language also highlights additional eligible applicants, including HBCUs, Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, regional organizations, eligible federal agencies, and foreign organizations (non-U.S. entities).
Are non-U.S. (foreign) organizations allowed to apply?
Yes. The FOA explicitly includes non-U.S. entities (foreign organizations) among eligible applicants.
Does this FOA require cost sharing or matching funds?
No. The FOA does not require cost sharing or matching funds.
What federal agency is administering this opportunity?
The primary federal agency is the National Institutes of Health (NIH).
How is this opportunity categorized administratively?
It is categorized as a discretionary grant within the health funding activity area and is tied to CFDA 93.310 (Trans-NIH Research Support), indicating that it aligns with a broader NIH-wide effort rather than being limited to a single institute or disease area.
When was the FOA posted, and what were the key dates?
The FOA was posted on July 16, 2009. The application due date was September 14, 2009. The archive date was October 15, 2009.
Where were applicants directed to find the full announcement and support contacts?
Applicants were directed to the NIH grants page for the full announcement. NIH Office of Extramural Research (OER) webmaster contacts were provided for access or linking issues.
What is the main objective of this FOA in plain language?
The main objective is to speed up and strengthen microbiome research by funding better tools and methods for isolating individual human-associated microbes and generating complete genome sequences from them, thereby improving the foundation of reference genomes needed for accurate microbiome analysis.
Browse more opportunities from the same category: Health
Next opportunity: Development of New Technologies Needed for Studying the Human Microbiome (R21)
Previous opportunity: Cooperative Ecosystem Studies Unit, Pacific Northwest CESU
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA RM 09 008
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA RM 09 008) also looked into and applied for these:
| Funding Opportunity |
|---|
| Development of New Technologies Needed for Studying the Human Microbiome (R21) Apply for RFA RM 09 009 Funding Number: RFA RM 09 009 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Epidemiological MCH/SPH Institute Apply for HRSA 09 265 Funding Number: HRSA 09 265 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Short Term Research Education Program to Increase Diversity in Health Related Research (R25) Apply for RFA HL 10 013 Funding Number: RFA HL 10 013 Agency: National Institutes of Health Category: Health Funding Amount: $106,250 |
| Revolutionary Genome Sequencing Technologies The 1000 Genome (R01) Apply for RFA HG 09 011 Funding Number: RFA HG 09 011 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Revolutionary Genome Sequencing Technologies The 1000 Genome (R21) Apply for RFA HG 09 012 Funding Number: RFA HG 09 012 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Revolutionary Genome Sequencing Technologies The 1000 Genome (SBIR R43/R44) Apply for RFA HG 09 013 Funding Number: RFA HG 09 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Awards to Support Research on the Biology of Aging in Invertebrates (R01) Apply for RFA AG 10 004 Funding Number: RFA AG 10 004 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| AHRQ Grants for Health Services Research Dissertation Program (R36) Apply for PAR 09 212 Funding Number: PAR 09 212 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $40,000 |
| Increasing Immunization Rates through Healthcare Provider Partnerships Apply for CDC RFA IP09 903 Funding Number: CDC RFA IP09 903 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Childhood Immunization Support Project Apply for CDC RFA IP09 904 Funding Number: CDC RFA IP09 904 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Rural Health Network Development Planning Grant Program Apply for HRSA 10 020 Funding Number: HRSA 10 020 Agency: Health Resources and Services Administration Category: Health Funding Amount: $85,000 |
| Coordination of Activities between the CDC, NCIRD, and State and Local Immunization Programs Apply for CDC RFA IP09 905 Funding Number: CDC RFA IP09 905 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $278,000 |
| Best Practices in Child Welfare Project Apply for USAID RUSSIA OH 09 0002 RFA Funding Number: USAID RUSSIA OH 09 0002 RFA Agency: Russia USAID Moscow Category: Health Funding Amount: $8,500,000 |
| Supplement for Implementing Training of the Sexually Transmitted Disease (STD) Program Management Course Apply for CDC RFA PS06 60601SUPP09 Funding Number: CDC RFA PS06 60601SUPP09 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Consortia for High Throughput Enabled Structural Biology Partnerships (U01) Apply for RFA GM 10 007 Funding Number: RFA GM 10 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers for Membrane Protein Structure Determination (U54) Apply for RFA GM 10 006 Funding Number: RFA GM 10 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAMS Building Interdisciplinary Research Team (BIRT) Revision Awards (R01) Apply for RFA AR 10 001 Funding Number: RFA AR 10 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition The National Institute on Aging Multicenter Study on Exceptional Survival in Families The Long Life Family Study (LLFS) (U01) Apply for RFA AG 10 005 Funding Number: RFA AG 10 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Partnerships for Development of Therapeutics and Diagnostics for Drug Resistant Bacteria and Eukaryotic Parasites (SBIR R43/R44) Apply for RFA AI 09 029 Funding Number: RFA AI 09 029 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Partnerships for Development of Therapeutics and Diagnostics for Drug Resistant Bacteria and Eukaryotic Parasites (R01) Apply for RFA AI 09 026 Funding Number: RFA AI 09 026 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA RM 09 008", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.